earticle

논문검색

Therapeutic antibody development based on efficacy and manufacturability

초록

영어

Therapeutic antibodies can be generated from many routes. At early stage of research, as many candidate antibodies as possible should be evaluated for optimal efficacy and manufacturability. For anti-cancer treatment, very high dose of antibody therapeutics are administered. Successful antibody development must overcome the challenge of high titer cell culture, maximum yield at down stream process, long-term stability in highconcentration formulation and optimal pharmacokinetic, pharmacodynamic property and minimum immunogenecity in human. How these issues could be managed at early stage of research will be discussed.

저자정보

  • Seungchul Jun R & D Center, ISU ABXIS, Korea

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

      0개의 논문이 장바구니에 담겼습니다.